异基因造血干细胞移植后复发防治新进展

刘燕平; 缪扣荣

doi:10.13201/j.issn.1004-2806.2023.03.015

异基因造血干细胞移植后复发防治新进展

刘燕平¹,
缪扣荣^1, ,

- 南京医科大学第一附属医院，江苏省人民医院血液科(南京，210029)

详细信息

通讯作者: 缪扣荣，E-mail：kourongmiao@163.com

中图分类号: R457.7

收稿日期: 2022-07-05

刊出日期: 2023-03-01

New progress in the prevention and treatment of relapse after allogeneic hematopoietic stem cell transplantation

LIU Yanping¹,
MIAO Kourong^1, ,

- Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China

More Information

Corresponding author: MIAO Kourong, E-mail: kourongmiao@163.com

Received Date: 05 July 2022

Publish Date: 01 March 2023

摘要

摘要: 异基因造血干细胞移植在急性白血病的治疗地位越来越突出，是目前具有治愈可能的重要治疗手段，但移植后复发仍是目前导致移植失败的主要原因之一。移植后复发患者的预后极差，目前尚无统一的治疗方案，是临床上面临的重大难题。文章将从移植后复发的风险识别、预防及治疗3个方面对急性白血病患者移植后复发的防治新进展作一综述。
- 异基因造血干细胞移植 /
- 复发 /
- 预防 /
- 治疗
Abstract: Allogeneic hematopoietic stem cell transplantation(allo-HSCT), with a curative potential, has been playing a critical role in the treatment of acute leukemia. However, relapse after allo-HSCT is still one of the most common causes of the failure after transplantation. Patients who relapse after transplantation has poor prognosis and no standard treatment is available. Treatment of patients who relapse after allo-HSCT remains a challenge in clinical practice. We reviewed the current progress in the prevention and treatment of acute leukemia relapsed after allo-HSCT from three aspects, including the risk identification of post-transplant relapse, the prevention and treatment of relapse.
- allogeneic hematopoietic stem cell transplantation /
- relapse /
- prevention /
- treatment

HTML全文

参考文献(41)

[1]	仲照东, 陈智超, 夏凌辉. 急性髓系白血病造血干细胞移植后复发的预防及治疗[J]. 临床血液学杂志, 2022, 35(5): 375-379. doi: 10.13201/j.issn.1004-2806.2022.05.015 https://lcxy.whuhzzs.com/article/doi/10.13201/j.issn.1004-2806.2022.05.015
[2]	Schuler E, Boughoufala S, Rautenberg C, et al. Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies[J]. Ann Hematol, 2019, 98(5): 1225-1235. doi: 10.1007/s00277-019-03670-6
[3]	Yanada M, Konuma T, Yamasaki S, et al. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes[J]. Bone Marrow Transplant, 2021, 56(5): 1126-1133. doi: 10.1038/s41409-020-01163-z
[4]	Zhao P, Ni M, Ma D, et al. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation[J]. Ann Hematol, 2022, 101(1): 119-130. doi: 10.1007/s00277-021-04674-x
[5]	Yan N, Wang N, Wang G, et al. CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation[J]. Cytotherapy, 2022, 24(8): 841-849. doi: 10.1016/j.jcyt.2022.01.011
[6]	Yoshimoto G, Mori Y, Kato K, et al. Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation[J]. Leuk Lymphoma, 2021, 62(12): 2939-2948. doi: 10.1080/10428194.2021.1941937
[7]	Orti G, Barba P, Fox L, et al. Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect[J]. Exp Hematol, 2017, 48: 1-11. doi: 10.1016/j.exphem.2016.12.004
[8]	Orvain C, Wilson JA, Fang M, et al. Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia[J]. Haematologica, 2023, 108(2): 420-432.
[9]	Ossenkoppele GJ, Janssen JJ, van de Loosdrecht AA. Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia[J]. Haematologica, 2016, 101(1): 20-25. doi: 10.3324/haematol.2015.139105
[10]	Shouval R, Fein JA, Labopin M, et al. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry[J]. Lancet Haematol, 2021, 8(3): e205-e215. doi: 10.1016/S2352-3026(20)30394-X
[11]	Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel[J]. Blood, 2017, 129(4): 424-447. doi: 10.1182/blood-2016-08-733196
[12]	Tracy SI, Cao Q, Bachan B, et al. Ph-like gene alterations and complex chromosomal abnormalities are frequent in patients with acute lymphoblastic leukemia experiencing relapse after allogeneic hematopoietic cell transplantation[J]. Eur J Haematol, 2022, 109(4): 406-408. doi: 10.1111/ejh.13814
[13]	Cao LQ, Zhou Y, Liu YR, et al. A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogenic stem cell transplantation[J]. Chin Med J(Engl), 2021, 134(10): 1199-1208.
[14]	Mo XD, Lv M, Huang XJ. Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease(MRD)monitoring and MRD-directed intervention[J]. Br J Haematol, 2017, 179(2): 184-197. doi: 10.1111/bjh.14778
[15]	Dillon R, Hills R, Freeman S, et al. Molecular MRD status and outcome after transplantation in NPM1-mutated AML[J]. Blood, 2020, 135(9): 680-688. doi: 10.1182/blood.2019002959
[16]	Pasvolsky O, Shimony S, Yeshurun M, et al. Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis[J]. Acta Oncol, 2021, 60(10): 1335-1341. doi: 10.1080/0284186X.2021.1955969
[17]	Wei Y, Cao Y, Jin X, et al. Low-dose decitabine plus venetoclax maintenance therapy can decrease the relapse after allogeneic stem cell transplantation for MRD positive high-risk acute myeloid leukemia and myelodysplastic syndrome[J]. Blood, 2020, 136(Supple): 33-33.
[18]	Kent A, Pollyea DA, Winters A, et al. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse[J]. Blood, 2020, 136(Suppl 1): 11-12.
[19]	Biavasco F, Zeiser R. FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation[J]. Int J Hematol, 2022, 116(3): 341-350. doi: 10.1007/s12185-022-03352-6
[20]	Mishra A, Tamari R, DeZern AE, et al. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes[J]. J Clin Oncol, 2022, 40(34): 3985-3993. doi: 10.1200/JCO.22.00181
[21]	Warraich Z, Tenneti P, Thai T, et al. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review[J]. Biol Blood Marrow Transplant, 2020, 26(3): e55-e64. doi: 10.1016/j.bbmt.2019.09.022
[22]	Gaballa MR, Banerjee P, Milton DR, et al. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia[J]. Blood, 2022, 139(12): 1908-1919. doi: 10.1182/blood.2021013290
[23]	Liu J, Jiang ZX, Xie XS, et al. Maintenance Treatment With Low-Dose Decitabine After Allogeneic Hematopoietic Cell Transplantation in Patients With Adult Acute Lymphoblastic Leukemia[J]. Front Oncol, 2021, 11: 710545. doi: 10.3389/fonc.2021.710545
[24]	Naik S, Vasileiou S, Tzannou I, et al. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL[J]. Blood, 2022, 139(17): 2706-2711. doi: 10.1182/blood.2021014648
[25]	Shen MZ, Zhang XH, Xu LP, et al. Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies[J]. Front Immunol, 2022, 13: 757002. doi: 10.3389/fimmu.2022.757002
[26]	Tessoulin B, Delaunay J, Chevallier P, et al. Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT[J]. Bone Marrow Transplant, 2014, 49(4): 567-571. doi: 10.1038/bmt.2013.233
[27]	Schroeder T, Czibere A, Platzbecker U, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation[J]. Leukemia, 2013, 27(6): 1229-1235. doi: 10.1038/leu.2013.7
[28]	Drozd-Sokolowska J, Karakulska-Prystupiuk E, Biecek P, et al. Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis[J]. Eur J Haematol, 2021, 107(1): 129-136. doi: 10.1111/ejh.13628
[29]	Harada K, Mizuno S, Yano S, et al. Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia[J]. Ann Hematol, 2022, 101(3): 643-653. doi: 10.1007/s00277-021-04731-5
[30]	Rettig AR, Ihorst G, Bertz H, et al. Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis[J]. Ann Hematol, 2021, 100(9): 2339-2350. doi: 10.1007/s00277-021-04494-z
[31]	Gyurkocza B, Storb R, Chauncey TR, et al. Second allogeneic hematopoietic cell transplantation for relapse after first allografts[J]. Leuk Lymphoma, 2019, 60(7): 1758-1766. doi: 10.1080/10428194.2018.1542149
[32]	Lojko-Dankowska A, Matuszak M, Bembnista E, et al. Second allogeneic hematopoietic stem cell transplantation in relapsed acute myeloid leukemia-retrospective analysis of the outcome[C]. Prague Congress Centre, European Cooperative Group for Bone Marrow Transplantation, 2022.
[33]	Cui Q, Qian C, Xu N, et al. CD38^－ directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation[J]. J Hematol Oncol, 2021, 14(1): 82. doi: 10.1186/s13045-021-01092-4
[34]	Liu S, Luo X, Zhang X, et al. Preemptive interferon-alpha treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT[J]. Sci Rep, 2020, 10(1): 20148. doi: 10.1038/s41598-020-77186-9
[35]	Stein AS, Kantarjian H, Gokbuget N, et al. Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2019, 25(8): 1498-1504. doi: 10.1016/j.bbmt.2019.04.010
[36]	Wu H, Cai Z, Shi J, et al. Blinatumomab for HLA loss relapse after haploidentical hematopoietic stem cell transplantation[J]. Am J Cancer Res, 2021, 11(6): 3111-3122. http://www.researchgate.net/publication/353221737_Blinatumomab_for_HLA_loss_relapse_after_haploidentical_hematopoietic_stem_cell_transplantation
[37]	Hill E, Morrison C, Kazandjian D. Daratumumab: a review of current indications and future directions[J]. Semin Oncol, 2022, 49(1): 48-59. doi: 10.1053/j.seminoncol.2022.01.008
[38]	Li ZH, Wang XX, Wen XP, et al. Daratumumab-containing regimen in the treatment of relapsed hematological malignancies in children after allogeneic stem cell transplantation[C]. Prague Congress Centre, European Cooperative Group for Bone Marrow Transplantation, 2022.
[39]	Zhang C, Wang XQ, Zhang RL, et al. Donor-derived CD19 CAR-T cell therapy of relapse of CD19^－ positive B-ALL post allotransplant[J]. Leukemia, 2021, 35(6): 1563-1570. doi: 10.1038/s41375-020-01056-6
[40]	Liu S, Deng B, Yin Z, et al. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation[J]. Am J Hematol, 2021, 96(6): 671-679. doi: 10.1002/ajh.26160
[41]	Wang T, Gao L, Hu X, et al. Chimeric Antigen Receptor-modified Donor Lymphocyte Infusion Improves the Survival of Acute Lymphoblastic Leukemia Patients With Relapsed Diseases After Allogeneic Hematopoietic Stem Cell Transplantation[J]. J Immunother, 2019, 42(3): 81-88. doi: 10.1097/CJI.0000000000000257